Management of dementia-related psychosis, agitation and aggression : a review of the pharmacology and clinical effects of potential drug candidates by unknown
Vol.:(0123456789)
CNS Drugs (2020) 34:243–268 
https://doi.org/10.1007/s40263-020-00707-7
REVIEW ARTICLE
Management of Dementia‑Related Psychosis, Agitation 
and Aggression: A Review of the Pharmacology and Clinical Effects 
of Potential Drug Candidates
Monika Marcinkowska1  · Joanna Śniecikowska1,2 · Nikola Fajkis1 · Paweł Paśko1 · Weronika Franczyk1 · 
Marcin Kołaczkowski1,2
Published online: 12 February 2020 
© The Author(s) 2020
Abstract
Along with cognitive decline, 90% of patients with dementia experience behavioral and psychological symptoms of dementia, 
such as psychosis, aggression, agitation, and depression. Atypical antipsychotics are commonly prescribed off-label to man-
age certain symptoms, despite warnings from the regulatory agencies regarding the increased risk of mortality associated 
with their use in elderly patients. Moreover, these compounds display a limited clinical efficacy, mostly owing to the fact 
that they were developed to treat schizophrenia, a disease characterized by neurobiological deficits. Thus, to improve clinical 
efficacy, it has been suggested that patients with dementia should be treated with exclusively designed and developed drugs 
that interact with pharmacologically relevant targets. Within this context, numerous studies have suggested druggable tar-
gets that might achieve therapeutically acceptable pharmacological profiles. Based on this, several different drug candidates 
have been proposed that are being investigated in clinical trials for behavioral and psychological symptoms of dementia. We 
highlight the recent advances toward the development of therapeutic agents for dementia-related psychosis and agitation/
aggression and discuss the relationship between the relevant biological targets and their etiology. In addition, we review 
the compounds that are in the early stage of development (discovery or preclinical phase) and those that are currently being 
investigated in clinical trials for dementia-related psychosis and agitation/aggression. We also discuss the mechanism of 
action of these compounds and their pharmacological utility in patients with dementia.
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1 Introduction
While describing the first case report of dementia, Alois 
Alzheimer indicated that along with memory impairment, 
the patient demonstrated symptoms of psychosis [1, 2]. 
Currently, it is widely recognized that neuropsychiatric dis-
turbances constitute an inherent component of Alzheimer’s 
disease (AD) and its related dementias. These manifesta-
tions are referred to in the literature as “behavioral and psy-
chological symptoms of dementia” (BPSD), which include 
psychosis, agitation, aggression, irritability, depression, 
and anxiety [3]. It is estimated that at least one or more 
behavioral symptoms will manifest in almost all patients 
with dementia in the course of their disease [4]. Behavioral 
and psychological symptoms of dementia can decrease the 
quality of patients’ lives and are often cited as the main rea-
son for referring patients with dementia to nursing homes or 
similar institutions [5].
Currently, a specifically approved pharmacotherapy for 
BPSD remains elusive. The most troublesome psychiatric 
events such as aggression and the remaining symptoms 
psychosis and agitation are addressed with atypical antip-
sychotics administered off-label [6]. However, the clinical 
efficacy of these drugs is unsatisfactory because a large 
percentage of patients do not respond or respond partially 
to the drugs [7]. Moreover, atypical antipsychotics are not 
actually recommended for elderly patients because they pose 
a risk of many side effects [8]. Elderly patients seem to be 
particularly sensitive to severe adverse reactions induced by 
atypical antipsychotics such as excessive sedation, orthos-
tatic hypotension and related complications such as falls, 
extrapyramidal symptoms, cognitive slowing, cardiovascular 
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Key Points 
Current pharmacotherapy of dementia-related psychosis 
and agitation/aggression relies on the off-label admin-
istration of atypical antipsychotics, which have limited 
clinical efficacy and induce various adverse reactions.
Genetic studies have suggested several druggable targets 
that correspond with the etiology of dementia-related 
psychosis and agitation/aggression: serotonin 5-HT2A 
and 5-HT1A receptors, serotonin transporter, alpha-1 
adrenoceptor, and dopamine  D1 and  D3 receptors.
Novel therapeutic approaches may benefit particularly 
from targeting the serotoninergic system with serotonin 
5-HT2A and 5-HT1A ligands or serotonin transporter 
inhibitors, which are currently being investigated in 
phase III clinical trials.
Preclinical and clinical studies have suggested other rel-
evant molecular targets that may result in therapeutically 
acceptable efficacy: cannabinoid receptors, metabotropic 
glutamate 2 receptors, muscarinic  M1/M4 receptors, and 
glutamate N-methyl-D-aspartate receptors.
Blockade of  M1, alpha-2 adrenergic, and histamine  H1 
receptors and the human ether-a-go-go-related gene 
channel should be avoided because elderly patients are 
particularly sensitive to adverse reactions induced by the 
drugs acting on these targets.
deficits that are distinct from BPSD. Aging induces changes 
in the quality and quantity of neurotransmitters, which may 
account for the onset of behavioral symptoms in patients 
with dementia [17, 18]. Consequently, fluctuations of neu-
rochemicals initiate changes in the expression of certain 
receptors that should be targeted with specific medications 
[19]. Thus, patients with dementia might benefit from drugs 
interacting with relevant molecular targets to maximize the 
clinical response.
In this regard, a plethora of experimental evidence has 
recently highlighted several druggable targets that are 
believed to achieve therapeutically acceptable pharmaco-
logical profiles for BPSD. Several different drug candidates 
are being investigated in clinical trials for BPSD, which 
hopefully will make the pharmacotherapy of BPSD a real-
istic prospect. In this review, we present the drug candi-
dates being currently investigated in clinical trials for BPSD. 
We focus on the most troublesome symptoms, aggression, 
agitation, and psychosis, which require pharmacological 
intervention. We discuss their pharmacological profile in 
terms of privileged biological targets, and assess how they 
correspond with the molecular mechanisms underlying 
their pathology. We also provide information on the latest 
investigational compounds at the early stage of development 
(discovery or preclinical phase). (For a review of the treat-
ment of depression in patients with dementia, the reader is 
referred elsewhere [20]).
2  Overview of Potential Druggable Targets 
for Pharmacological Treatment Matching 
the Etiology of Dementia‑Related 
Psychosis and Agitation/Aggression
The etiology of dementia-related psychosis and agitation/
aggression is very complex and is often a cluster of bio-
logical factors (anatomical and neurochemical changes) as 
well as psychological and social aspects (responses to stress, 
living arrangements [21]). Alzheimer’s disease is the most 
common type of dementia, and the pathophysiology of this 
particular disease is related to the loss of neurons. Depend-
ing on the degree of neurodegeneration, the cerebral region 
involved, and consequently the extent of deficits in neuro-
transmitters, various psychiatric symptoms may appear [22]. 
For instance, psychosis has been associated with neurode-
generation in the frontal and mesotemporal areas of the brain 
[23], while depression has been linked to the degeneration 
of brainstem aminergic nuclei and a decrease in serotoner-
gic neurotransmission [24]. Additionally, neuropathologi-
cal changes that cause hypofunction of the cholinergic and 
serotonergic systems and hyperfunction of dopaminergic 
and noradrenergic transmission have been linked to agita-
tion manifested by patients with dementia [22]. Alterations 
complications, and anticholinergic side effects [9]. Notably, 
the use of currently available antipsychotics in patients 
with dementia has been associated with an increased risk of 
death. Consequently, in April 2004, the US Food and Drug 
Administration (FDA) issued a black-box warning against 
the use of atypical antipsychotics in elderly patients [10, 
11]. The American and British clinical guidelines [12–14] 
state that antipsychotics can be used only if the patient con-
stitutes a threat to self or others and should be administered 
after evaluating the benefit/risk ratio of the treatment [15]. 
If the physician decides to prescribe antipsychotics, clinical 
guidelines recommend the exclusive usage of the following 
drugs: risperidone, olanzapine, quetiapine, and aripiprazole 
[12]. Nevertheless, several reviews in this subject empha-
sized that prior to treatment with antipsychotics, one should 
always consider that these drugs exert detrimental effects 
and provide limited efficacy [6, 7, 16].
The main explanation for the poor clinical performance of 
atypical antipsychotics in elderly patients is that these were 
approved specifically for the treatment of schizophrenia, 
which affects mostly younger adults with neurobiological 
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in multiple neurotransmitter systems cause changes in the 
expression of specific receptors, which have a direct impact 
on the regular functioning of the central nervous system 
(CNS) [3, 18].
Numerous studies have revealed a close association 
between genetic polymorphisms and the onset of psychiatric 
symptoms in patients with dementia. Particularly, serotonin 
5-HT2A receptors (5-HT2AR) are related to the etiopathology 
of dementia-related psychosis and aggression. For instance, 
in patients with dementia, 5-HT2AR binding is decreased 
[25]. Additionally, reduced density of 5-HT2AR in the pre-
frontal cortex [26] and the polymorphism of 5-HT2AR have 
been associated with an increased risk of hallucinations and 
aggression [26, 27]. Moreover, the type of hallucinations 
observed in patients with Lewy body dementia (mainly vis-
ual) suggests the involvement of serotonin 5-HT2AR [28]. In 
fact, these resemble the hallucinations induced by 5-HT2AR 
agonists lysergic acid diethylamide and mescaline rather 
than those found in patients with schizophrenia, which tend 
to be mainly auditory [29–31]. Therefore, compounds that 
preferentially block 5-HT2AR might be used to treat demen-
tia-related psychosis or aggression.
Similarly, other molecular targets have been associated 
with the manifestation of psychiatric symptoms in patients 
with dementia. A genetic study showed that the polymor-
phism of the serotonin transporter (SERT) promoter region 
(L/L genotype) is correlated with aggressive behavior in 
patients with AD [32, 33]. Furthermore, decreased den-
sity of 5-HT1AR in the cortex has been directly linked with 
the onset of aggressive behavior in patients with AD [34]. 
Furthermore, postmortem studies in patients with AD indi-
cated that neurodegeneration of noradrenergic neurons may 
account for the pathophysiology of agitation and aggression 
related to AD [35]. In addition, polymorphisms in dopamine 
 D1 receptor  (D1R) and  D3 receptors  (D3R) have been associ-
ated with dementia-related psychosis and aggression [36]. In 
summary, potential druggable targets that closely correspond 
with the pathology of dementia-related psychosis, agitation, 
and aggression include serotonin 5-HT2AR and 5-HT1AR, 
SERT, alpha-1 adrenoceptors, and  D1R and  D3R.
Preclinical studies disclosed another palette of interesting 
molecular targets that may exhibit therapeutically relevant 
pharmacological profiles. For instance, an experimental 
study showed that knockout mice deficient in the cannabi-
noid  CB1 receptor  (CB1R) displayed aggressive behavior, 
which could be reduced by the short-term administration 
of a  CB1R agonist [37]. Clinical evidence showed that the 
cortical areas in patients with AD are characterized by 
reduced expression and decreased availability of  CB1R [38]. 
Therefore, pharmacological modulation of  CB1R deserves a 
broadened evaluation to consider it as a potential molecular 
target in the management of AD-related aggression [39]. 
Furthermore, many findings suggest that neurodegeneration 
induces changes in the expression and function of metabo-
tropic glutamate receptors (mGluRs) and N-methyl-d-as-
partate (NMDA) receptors [40]. Disrupted glutamatergic 
neurotransmission, in turn, is a well-recognized factor that 
contributes to the pathophysiology of neuropsychiatric dis-
orders [41, 42]. Studies in animal models revealed that the 
activation of metabotropic glutamate 2 receptor (mGlu2R) 
resulted in antipsychotic, memory-enhancing [43], and 
neuroprotective activity [44], while modulation of NMDA 
receptors is crucial for neuroplasticity and also influences 
mood and behavior [40]. Therefore, while developing drugs 
for dementia-related psychosis in the future, those targeting 
mGluRs or NMDA receptors can be considered as poten-
tial pharmacological targets. Furthermore, pharmacological 
activation of muscarinic receptors  M1/M4  (M1R/M4R) may 
represent a disease-modifying [45] and symptomatic treat-
ment [46]. Stimulation of  M1R/M4R mediates key effects 
on cognitive performance, protects neurons from beta-amy-
loid toxicity [45], and promotes antipsychotic activity [46]. 
In addition, mounting evidence shows that patients with 
dementia may benefit from drugs targeting serotonin 5-HT6 
receptors (5-HT6R) [47]. Preclinical studies revealed that 
selective 5-HT6R antagonists display promising procogni-
tive activity, as well as mood-modulating properties [48]. A 
summary of the potential molecular targets for the treatment 
of dementia-related psychosis and agitation/aggression is 
presented in Table 1.
3  New Drug Candidates on the Horizon
3.1  Identification of Compounds Investigated 
in Preclinical and Clinical Trials
To collect data regarding the compounds being investigated 
in clinical trials, we searched for trials registered by the US 
National Institutes of Health (http://www.clini caltr ials.gov) 
and EudraCT (https ://eudra ct.ema.europ a.eu) using the fol-
lowing keywords: “dementia” or “Alzheimer’s disease” and/
or “agitation,” and/or “aggression” and/or “psychosis.” We 
restricted the search for trials from 2014 to present to obtain 
the most recent overview covering the last 5 years. Addi-
tionally, we searched for literature data associated with the 
identified compounds, published from 2014 to the present, 
using the compounds’ name and other keywords such as 
“Alzheimer’s disease” and “dementia” or “aggression” or 
“psychosis.” We used PubMed, ScienceDirect, GlobalData, 
and Google Scholar databases. If data regarding a com-
pound’s efficacy or the current status of its trial were not 
published or posted on clinical trial registries, we searched 
the websites of the pharmaceutical and biotech companies 
responsible for that compound’s development. The search 
was restricted to English.
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The applied search resulted in the identification of several 
drug candidates being investigated in clinical trials. Table 2 
summarizes the data extracted on the investigated drug can-
didates, which will be discussed in detail below (except for 
lithium, which has been reviewed comprehensively else-
where [49, 50]).
4  Drug Candidates for Dementia‑Related 
Psychosis and Agitation/Aggression 
in Clinical Trials
4.1  Drugs Affecting Serotonergic 
Neurotransmission
4.1.1  Serotonin 5‑HT2A Receptor Inverse Agonist: 
Pimavanserin
Among the various molecular targets considered as poten-
tial treatments of dementia-related psychosis or agitation/
aggression, serotonin receptors have come into the lime-
light. Age-related decline in serotonin function has been 
linked with aggressive behavior in AD [77, 78]. Specifi-
cally, a reduced density and polymorphism of 5-HT2AR have 
been observed with the onset of aggression and psychosis 
in patients with dementia [77]. Therefore, modulation of 
the activity of 5-HT2AR seems to be a promising therapeu-
tic strategy for reducing psychiatric symptoms that matches 
closely with the disease pathology.
A serotonin 5-HT2AR inverse agonist, pimavanserin, has 
been proposed as a suitable agent for the treatment of demen-
tia-related psychosis and agitation/aggression [79, 80]. 
Pimavanserin was the first antipsychotic agent approved by 
the FDA (in 2016) for the treatment of psychosis in patients 
with Parkinson’s disease. It is a nondopaminergic, highly 
selective 5-HT2A inverse agonist that acts predominantly on 
the 5-HT2AR and, to a lesser degree, on another serotonin 
receptor subtype 5-HT2C (Fig. 1) [81]. Pimavanserin displays 
no affinity to the other G protein-coupled receptors includ-
ing dopaminergic, histaminergic, muscarinic, and adrenergic 
receptors [82]. Thus, it is believed that this compound does 
not induce adverse reactions that are characteristic of atypi-
cal antipsychotics. The unique pharmacological profile of 
pimavanserin is characterized by high affinity and specific 
functional activity at the 5-HT2AR. As an inverse agonist, 
pimavanserin binds to the 5-HT2AR and not only blocks its 
natural agonistic activity but also reduces its constitutive 
activity. Importantly, pimavanserin does not bind to striatal 
 D2 receptors, which indicates a high margin of safety in 
terms of the extrapyramidal side effects [83].
Preclinical studies revealed that pimavanserin reduced 
psychotic-like behavior in rodents [84, 85]. In clinical tri-
als, pimavanserin was found to be effective in the treatment 
of delusions and hallucinations associated with Parkinson’s 
disease [86]. These promising results encouraged the evalua-
tion of the efficacy of this agent in other psychotic disorders, 
including AD-related psychosis. Recently, a phase II, ran-
domized, double-blind, placebo-controlled study evaluated 
the efficacy of pimavanserin in patients with AD-related 
psychosis (NCT02035553) [57, 58]. In the study, 181 sub-
jects with AD were enrolled and treated with pimavanserin 
(17 mg twice daily) for 12 weeks (Table 3). Pimavanserin 
showed a statistically superior effect to placebo (change in 
the psychosis score on Neuropsychiatric Inventory [NPI]-
Nursing Home Version scale) and an acceptable tolerability 
profile with no undesirable side effects on cognition [58]. 
The sponsor (ACADIA Pharmaceuticals) is currently run-
ning a phase III study, 52-week, open-label extension study 
(registered in Europe:2017-004439-36) of pimavanserin in 
the treatment of psychotic symptoms and agitation in 750 
patients with dementia [65].
As psychotic symptoms in patients with AD tend to remit 
and relapse [87], it has been suggested that it would be desir-
able to further evaluate the efficacy of pimavanserin in pre-
venting psychotic symptoms in patients with AD. In this 
regard, a double-blind, placebo-controlled, phase III study 
(NCT03325556) is currently recruiting 356 participants to 
evaluate the efficacy of pimavanserin (34 mg once daily) 
in preventing the relapse of psychotic episodes in patients 
with dementia (primary outcome measure: time from 
Table 1  Summary of the potential druggable targets that might be suitable for pharmacological modulation of selected behavioral and psycho-
logical symptoms of dementia (BPSD): psychosis, aggression, and agitation
Matching with BPSD pathology Indicated by experimental studies
Target Pharmacological activity Target Pharmacological activity
Serotonin 5-HT2A receptors Antipsychotic, antiaggressive Muscarinic  M1/M2 receptors Antipsychotic, procognitive
Serotonin 5-HT1A receptors Antiaggressive Cannabinoid receptor  CB1 Antiaggressive
Serotonin transporter Antiaggressive Metabotrophic glutamate 2 recep-
tor (mGlu2)
Antipsychotic
Dopamine  D1,  D2 receptors Antipsychotic, antiaggressive Serotonin 5-HT6 receptors Procognitive, anxiolytic
Alpha-1 adrenoreceptor Antiaggressive
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randomization to relapse in the double-blind period, up to 
26 weeks) [62]. In parallel, the sponsor is running a phase III 
study registered in Europe (2017-002227-13), which evalu-
ates the efficacy of pimavanserin in relapse prevention of 
psychotic symptoms in 212 patients with dementia [66]. In 
addition, a phase II open-label study (NCT03118947) [64] 
has been completed recently. The study evaluated the safety 
and tolerability of pimavanserin (10 or 17 mg twice daily, 
primary outcome measure: treatment-emergent adverse 
events [Table 3]). The results have not been revealed yet.
4.1.2  Serotonin 5‑HT1A/1B Receptor Agonist: Eltoprazine
Previous findings revealed that aggressive behaviors in 
patients with AD directly correlate with a reduced density 
of 5-HT1AR in the CNS [34]. Several clinical reports dis-
closed a significant reduction in agitation and aggression 
in patients with dementia after the administration of drugs 
acting via 5-HT1AR: tandospirone [88] and buspirone [89]. 
Therefore, it has been suggested that modulation of the 
activity of 5-HT1AR might be considered as a promising 
therapeutic strategy for the treatment of dementia-related 
agitation/aggression.
Eltoprazine was developed as an anti-aggressive agent 
[90–92]. It was reported that eltoprazine potently suppressed 
aggressive behavior in animal models without causing seda-
tion [93, 94]. Eltoprazine is a 5-HT1A/5-HT1B partial ago-
nist but also acts as a full agonist at 5-HT2CR (Fig. 2) [96]. 
Its anti-aggressive properties most probably result from the 
reduction in serotonin release due to the activation of pre-
synaptic 5-HT1A and 5-HT1B autoreceptors [97, 98]. Moreo-
ver, mixed 5-HT1A/5-HT1B partial agonism of eltoprazine is 
responsible for its highly effective inhibition of aggressive 
behavior [98].
In phase I of clinical trials, eltoprazine was found to be 
safe and well tolerated [97]. In a phase II study on the treat-
ment of AD-related aggression, eltoprazine showed prom-
ising results [52]. This double-blind, randomized, placebo-
controlled study found that eltoprazine (10 mg once daily 





































































































































































































































































































































Fig. 1  Structure and receptor profile of pimavanserin [81]
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(evaluated by the Social Dysfunction and Aggression Scale 
and the Staff Observation Scale) in 29 subjects (Table 3). 
These encouraging results suggest that further phase III 
clinical studies should be conducted on this indication.
4.1.3  Selective Serotonin Reuptake Inhibitors
Genetic studies revealed that certain forms of the SERT have 
been linked with the onset of dementia-related psychosis 
and aggressive behavior [32, 33]. In addition, administra-
tion of the selective serotonin reuptake inhibitor citalopram 
resulted in a significant decrease in the pathological levels of 
amyloid-β in patients with AD [99]. Preclinical studies have 
shown that citalopram blocked the growth of pre-existing 
amyloid-β plaques and reduced the formation of new plaques 
by 78% [100]. Moreover, selective serotonin reuptake inhibi-
tors increase the levels of serotonin and thus may stimulate 
hippocampal neurogenesis [101]. Therefore, administration 
of the drugs acting on SERT to mitigate behavioral symp-
toms in patients with dementia is a rational intervention.
One of the first studies showed the effectiveness of cit-
alopram in a short-term in-hospital management program of 
dementia-related aggression and agitation in patients with 
dementia [102]. These preliminary data have been confirmed 
in a larger randomized, placebo-controlled, double-blind 
study (NCT00898807) that enrolled 186 patients with AD 
[103] (Table 3). The study showed that long-term adminis-
tration of citalopram (10–30 mg/day for 3 weeks) led to a 
clinically meaningful reduction in the AD-associated agi-
tation compared with placebo (primary outcome measured 
by the Neurobehavioral Rating Scale Agitation subscale). 
However, treatment with citalopram has been associated 
with mild cognitive decline and cardiac side effects (QT 
interval prolongation), which hampers its long-term clinical 
application. In fact, in August 2011, the FDA announced a 
safety warning recommending to limit the maximum dose of 
citalopram to 20 mg/day in elderly patients aged > 60 years 
because of the possible occurrence of QT prolongation 
[104]. Therefore, it has been suggested that lower doses 
(< 30 mg/day) of citalopram [103] or alternatively other 
non-cardiotoxic antidepressants should be evaluated in clini-
cal trials [105].
An (S)-stereoisomer of citalopram (Fig. 3), escitalopram, 
seems to be safer, as the magnitude of QT prolongation 
observed with this compound is lower compared with cit-
alopram and the effect is dose dependent [106–108]. A rand-
omized, double-blind, pilot study evaluated the effectiveness 
of escitalopram (5–10 mg/day) in reducing psychotic symp-
toms and agitation in 40 patients with AD in a 6-week treat-
ment period (primary outcome measure: change in the total 
score on NPI), in comparison to the antipsychotic risperi-
done (0.5–1.0 mg/day) [109]. This study found that escitalo-
pram and risperidone were equally effective (Table 3) [110]. 
The authors did not observe any adverse event in the escital-
opram group. This pilot study justified the need for a larger, 
more comprehensive study. Currently, a phase III, double-
blind, randomized, placebo-controlled trial (NCT03108846) 
[67] is recruiting patients with AD-related dementia and 
clinically significant agitation (392 participants) to evalu-
ate the safety and effectiveness of escitalopram at a dose 
of 5–15 mg/day in reducing agitation in patients with AD 
during 12 weeks (primary outcome measure: change in the 
modified Alzheimer’s Disease Cooperative Study-Clinical 
Global Impression of Change score after 12 weeks) [67].
4.2  Drugs Acting on Several Biological Targets
4.2.1  Novel Atypical Antipsychotics
Recently, two novel atypical antipsychotic agents have 
been investigated in phase III clinical trials for AD-related 
agitation and psychosis: brexpiprazole and lumateperone. 
These agents target primarily the serotonin 5-HT2ARs while 
maintaining a relatively weaker interaction with  D2R, which 
makes them less likely to induce unfavorable extrapyrami-
dal side effects. Elderly patients are particularly sensitive to 
extrapyramidal symptoms [111] owing to an aging-related 
impairment of dopamine function [112]; therefore, the inter-
action of these agents with the  D2R should be retained at the 
lowest level.








5-HT1A Ki = 40 nM
5-HT1B Ki = 52 nM
5-HT2C Ki = 81 nM
Fig. 3  Chemical structure and binding profile of citalopram and escit-
alopram [107]. SERT serotonin transporter
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Brexpiprazole is a novel atypical antipsychotic approved 
by the FDA in 2015 for the treatment of schizophrenia and 
major depressive disorder as an add-on therapy [113]. Its 
mechanism of action is mediated via the antagonism of 
5-HT2AR and partial agonism of  D2R and 5-HT1AR (Fig. 4) 
[68]. Partial agonistic activity at the  D2 receptor accounts 
for the reduced occurrence of extrapyramidal side effects. 
Lately, two phase III clinical trials have evaluated the 
safety and efficacy of brexpiprazole in AD-related agita-
tion (NCT01862640 investigated two-fixed doses of 1 and 
2 mg/day and NCT01922258 investigated the flexible dosing 
of 0.5, 1.0, or 2.0 mg/day during the 12-week treatment). 
These randomized, double-blind, placebo-controlled, multi-
center studies enrolled 433 and 270 participants, respectively 
(Table 3). The sponsor announced that brexpiprazole signifi-
cantly ameliorated the symptoms of agitation in compari-
son to placebo (evaluated by a change from baseline in the 
Cohen-Mansfield Agitation Inventory [CMAI] total score) 
[114, 115]. A corresponding trial (phase III, 12-week, multi-
center, randomized, double-blind, placebo-controlled, two-
arm, fixed-dose: 0.5 mg and 1 mg, 225 patients) registered 
in Europe (2017-003940-19) has not been accomplished yet 
[70]. In addition, a phase III, multi-center, active-treatment-
extension trial (NCT03724942) is recruiting 250 patients to 
evaluate the safety and tolerability of brexpiprazole (2–3 mg/
day for 12 weeks) in patients with AD-associated agitation 
(primary outcome data will include adverse events elic-
ited from participants) [116]. A corresponding European 
active-treatment extension trial (a phase III, 12-week, multi-
center study, 225 patients with dementia) is ongoing (2018-
002783-88 [70]).
Lumateperone is another atypical antipsychotic drug with 
a mechanism of action based on the antagonistic activity at 
the 5-HT2AR, partial agonistic activity at the presynaptic 
 D2 receptors, and antagonistic activity at the postsynaptic 
 D2R [72, 117], as well as SERT blockade (Fig. 4). Clinical 
studies in healthy volunteers using positron emission tomog-
raphy revealed that lumateperone displayed high occupancy 
of the 5-HT2AR in the cortex and negligible occupancy of 
the  D2 striatal receptors [118], suggesting that it is less likely 
to induce extrapyramidal side effects. Lumateperone has a 
unique mechanism of action, modulating synergistically 
multiple neurotransmitter systems, and has been suggested 
as a potential treatment for a range of neuropsychiatric dis-
orders [73]. A recently completed phase III, randomized, 
double-blind, placebo-controlled, multi-center study 
(NCT02817906) has investigated the efficacy and safety 
of lumateperone (9 mg/day for 4 weeks; primary outcome 
measured using CMAI-Community Version) in 177 patients 
with dementia with clinically significant agitation (Table 3). 
The sponsor announced that the study was unlikely to meet 
its primary endpoint upon completion [119], and therefore, 
it has been terminated.
4.2.2  Dextromethorphan Formulations
Preclinical data revealed that a sigma-1 receptor agonist, 
dextromethorphan, exerts promising mood-modulating 
properties [121] For instance, dextromethorphan showed 
anti-stress activity by reducing fear stress in conditioned 
mice, which was suggested to involve a sigma-1-depend-
ent stimulation of the dopaminergic system [121]. Further 
studies in rodents revealed that dextromethorphan displayed 
anti-depressive-like activity and exerted neuroprotective and 
antioxidant effects [122, 123]. Dextromethorphan is an FDA-
approved antitussive drug that acts in the CNS [124, 125]. 
Dextromethorphan exhibits high affinity to several biological 
targets: sigma-1 receptor, SERT, norepinephrine transporter, 
NMDA receptor, alpha-2 adrenoceptor, histamine  H1 recep-
tor  (H1R), and nicotinic α3β4 receptor (Fig. 5) [124].
The specific receptor profile of dextromethorphan con-
tributes to its complex pharmacological activities, which 
prompted scientists to investigate its therapeutic potential 
in dementia-related agitation. However, dextromethorphan 
showed an unfavorable pharmacokinetic profile in humans, 
related to its rapid hepatic metabolism, which hampered 
the attainment of therapeutic concentrations in the brain. 
To reduce the first-pass effect and improve its pharmacoki-
netics, dextromethorphan was combined with a cytochrome 
P450 2D6 inhibitor, quinidine (formulation known as 
Fig. 4  Chemical structures and 
receptor profiles of brexpipra-
zole and lumateperone [68, 72]. 
SERT serotonin transporter
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AVP-923). Quinidine is an anti-arrhythmic agent used in 
clinical practice (200–300 mg) to treat cardiac arrhythmias 
[124, 126]. It reversibly inhibits cytochrome P450 2D6, and 
has been added to formulations at subclinical doses (10 mg) 
to inhibit cytochrome P450 2D6 and prolong the plasma 
half-life of dextromethorphan [124]. AVP-923 (Neudexta) 
has been approved by the FDA for the treatment of pseudob-
ulbar affect [127].
The first clinical study, a phase II, randomized, 
multi-center, double-blind, placebo-controlled trial 
(NCT01584440), evaluated the efficacy of AVP-923 (dex-
tromethorphan/quinidine at the doses of 20/10 mg once daily 
to 30/10 mg twice daily for 10 weeks) in reducing agitation 
in 220 patients with dementia, and revealed that AVP-923 
exerted statistically significant effects on agitation compared 
with placebo (primary outcome measure was the change from 
baseline in the NPI Agitation/Aggression domain score) 
[128] (Table 3). Meanwhile, another formulation had been 
developed, containing a subclinical dose of quinidine and 
deuterated dextromethorphan (AVP-786). Dextrometho-
rphan (Fig. 5) was deuterated to additionally improve its 
pharmacokinetic profile and reduce its first-pass metabolism 
in the liver [126]. Using the data generated for AVP-923, the 
FDA agreed to initiate a follow-up, phase III clinical trial 
(NCT02446132), an extension study, to evaluate the long-
term safety and efficacy of AVP-786 (three various doses 
administered twice a day over 52 weeks) in the management 
of dementia-associated agitation [129]. The primary outcome 
measure includes, inter alia, the number of participants with 
any treatment-emergent serious adverse event, the Mini-Men-
tal State Examination score, and the Alzheimer’s Disease 
Assessment Scale-Cognitive Subscale score [74].
Based on the promising results of previous studies, 
experts strongly believe that AVP-786 may become the 
first FDA-approved deuterated compound for the treatment 
of dementia-related agitation [126]. However, it should 
be emphasized that the first dextromethorphan/quinidine 
formulation (AVP-923, Neudexta) label carries a warning 
regarding cardiac safety [127], suggesting that this com-
pound should be avoided in patients with congenital long-
QT syndrome and the QTc interval should be evaluated in 
the patients at risk of QTc prolongation [126, 127].
Another combination formula that includes dextrometho-
rphan is AXS-05, which contains low doses of bupropion. 
Bupropion inhibits the reuptake of norepinephrine and 
dopamine and antagonizes nicotinic receptors. As a potent 
cytochrome P450 2D6 inhibitor, bupropion was added to the 
formulation to increase the plasma concentrations of dex-
tromethorphan [130]. AXS-05 received a fast-track desig-
nation from the FDA for the evaluation of its efficacy in the 
treatment of AD-related agitation [131]. Currently, a phase 
II/III clinical trial (NCT03226522) [62] is evaluating the 
safety and efficacy of AXS-05 (one tablet daily for 5 weeks) 
for its use in the management of AD-related agitation (pri-
mary outcome measured using CMAI). This randomized, 
double-blind, placebo-controlled study enrolled 435 subjects 
with AD. Recently, the sponsor has announced the positive 
outcome of the interim analysis of the study and received 
recommendation for further continuation [63].
4.3  Drugs Affecting Glutamatergic 
Neurotransmission
4.3.1  Metabotropic Glutamate 2 Receptor Agonist: 
LY2812223
In the early 1990s, it was first proposed that dysfunction 
in glutamatergic neurotransmission could be implicated in 
Fig. 5  Chemical structure of deuterated (d6) dextromethorphan/quinidine (AVP-786) and dextromethorphan/bupropion (AXS-05). NET 
noradrenaline transporter, NMDA N-methyl-d-aspartate, SERT serotonin transporter
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mental disorders [132]. Therefore, it was postulated that 
modulation of glutamatergic activity may constitute a novel 
nondopaminergic strategy for the treatment of psychosis 
[133–135]. Additionally, previous studies highlighted the 
activation of glutamate receptors exerts neuroprotective and 
memory-enhancing effects in animal models, which might 
be particularly beneficial to patients with dementia [42]. 
Eli Lilly and Company discovered LY2812223 (Fig. 6), a 
mGluR2 agonist [136, 137]. LY2812223 was found active 
in an animal model of psychosis, sensitive to mGluR2 
[95, 137]. Unfortunately, in the pharmacokinetic studies, 
LY2812223 showed a poor oral bioavailability (~ 4%). 
However, this did not limit the further development of the 
mGluR2 agonist for the treatment of mental disorders. Low 
bioavailability of LY2812223 was overcome by design-
ing its alanine prodrug MP-101 (LY2979165). MP-101 is 
administered orally and absorbed in the gastrointestinal tract 
through active transport and then, it is rapidly hydrolyzed to 
LY281223 (Fig. 6) [95, 138].
MP-101 is under development for the treatment of 
dementia-related psychosis and/or agitation and aggres-
sion (NCT03044249) [139]. This randomized, placebo-
controlled, phase II clinical trial will assess the efficacy 
(measured as the change from baseline in the NPI-Psycho-
sis subscale score), safety, and pharmacokinetic profile of 
MP-101 (20–60 mg/day for 10 weeks), compared to placebo. 
LY2979165 was previously evaluated in healthy subjects, 
in whom it was overall well tolerated and showed a linear 
pharmacokinetic profile [53, 137].
4.3.2  Inhibitors of D‑Amino Acid Oxidase
An interesting approach for indirectly controlling the glu-
tamatergic neurotransmission is to inhibit the activity of 
D-amino acid oxidase (DAAO). D-amino acid oxidase 
regulates the brain levels of D-amino acids, and in several 
psychiatric conditions, the activity and expression of DAAO 
are enhanced [140]. Overactivation of DAAO decreases the 
availability of d-serine, an endogenous agonist of the NMDA 
receptor. N-methyl-D-aspartate dysfunction in turn has been 
associated with schizophrenia and AD [141]. D-amino acid 
oxidase inhibitors were found to exert antipsychotic activ-
ity and improve cognitive function in AD [142, 143]. Cur-
rently, SyneuRx International Corp. is developing a com-
petitive antagonist of DAAO, compound SND-51, for the 
treatment of dementia and psychosis. SND-51 is botanic 
in origin (chemical structure has not been disclosed), and 
in animal models, it elicited antipsychotic and anxiolytic 
activity and improved spatial memory [144]. SND-51 has 
now progressed to phase II clinical trials, and its efficacy in 
the treatment of dementia and psychosis is being evaluated 
[145].
4.4  Drugs Affecting Cholinergic Neurotransmission
4.4.1  Selective Muscarinic  M4 Receptor Agonist: 
HTL0016878
Another promising example of compounds being developed 
for treating dementia-related psychosis and agitation/aggres-
sion is the selective muscarinic  M4R agonist HTL0016878 
(chemical structure has not been disclosed). The muscarinic 
receptors are abundantly expressed in the cortex and hip-
pocampus, the areas involved in cognitive and neurobehav-
ioral functions [146]. In animal models, nonselective  M1R/
M4R agonists improved psychotic behaviors and cognitive 
performance [46]. These findings have been confirmed in 
muscarinic  M4R-knockout mice, and thus, it has been sug-
gested that  M4R agonists represent an attractive molecular 
target for the development of novel antipsychotic agents 
[120]. A first-in-class selective  M4R agonist, HTL0016878, 
developed by Sosei Heptares for the treatment of neurobe-
havioral symptoms in patients with AD, has advanced to 
phase I clinical trials (NCT03244228). This randomized, 
double-blind, placebo-controlled study evaluated the safety, 
pharmacokinetics, and pharmacodynamics of this compound 
in 106 healthy young volunteers as well as in elderly patients 
[51]. The results have not been revealed yet.
4.5  Drugs Affecting Noradrenergic 
Neurotransmission
4.5.1  Alpha‑1 Adrenoceptor Inhibitor: Prazosin
Several findings indicated the robust association between 
noradrenergic depletion and AD [35, 147, 148]. Postmor-
tem studies revealed that the prefrontal cortex in patients 
with AD was characterized by a significant reduction in 
noradrenergic neurons [148], which may be associated 
with a poor cognitive performance as well as the onset of 


























hmGluR2 Ki = 144 
hmGluR2 EC50 = 5.6 nM,
Emax = 99% (cAMP assay)
Fig. 6  Chemical structure and metabolic activation of MP-101, a 
prodrug of LY281223. cAMP cyclic adenosine monophosphate, 
hmGluR2 human metabotropic glutamate receptor type 2
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compensatory upregulation of postsynaptic alpha-1 adreno-
ceptor is linked with AD-related aggression [149, 150]. 
Therefore, it has been proposed that reducing the activity of 
the overstimulated postsynaptic alpha-1 adrenoceptors may 
alleviate the aggressive behavior [151, 152].
Among dugs acting on the alpha-1 adrenoceptors, prazo-
sin remains the only centrally acting agent that can readily 
pass the blood–brain barrier and block the alpha-1 adreno-
ceptors in the CNS (Fig. 7) [153]. The first pilot study that 
evaluated the effectiveness of prazosin in suppressing the 
dementia-related aggression and agitation was a double-
blind placebo-controlled study that enrolled 22 patients with 
AD [151] (Table 3). Administration of prazosin (mean dose: 
5.7 mg/day, 8 weeks) led to a significant reduction in aggres-
sion/agitation (improvement on the Brief Psychiatric Rat-
ing Scale and the NPI score) compared with placebo [151]. 
Side effects and blood pressure fluctuations were compa-
rable between the prazosin group and the placebo group. 
These data provided further support to initiate a larger phase 
II study (NCT03710642) enrolling 186 patients with AD 
with agitation [55]. This double-blind, placebo-controlled, 
randomized study will evaluate the effectiveness of prazo-
sin (4–6 mg/day) in reducing agitation in patients with AD 
during 12 weeks (primary outcome measured using Clinical 
Global Impression of Change in Agitation) [55].
4.6  Drugs Targeting the Endocannabinoid System
Targeting cannabinoid receptors has acquired paramount 
importance as it offers a perspective to treat the symptoma-
tology and pathology of AD [156]. Activation of cannabi-
noid receptors by agonists at non-psychoactive doses induces 
neuroprotective effects [157, 158] and can influence mood 
and behavior [156]. Preclinical studies have shown that can-
nabinoid receptor agonists decrease amyloid-β levels and 
reduce neuroinflammation [159, 160]. Further preclinical 
studies showed that a cannabinoid receptor agonist reduced 
aggressive behaviors [37, 161, 162]. These data suggest that 
cannabinoid receptor agonists may serve as a potential treat-
ment for managing AD-related aggression.
Among the various cannabinoid receptor agonists, Δ-9-
tetrahydrocannabinol (THC), dronabinol, and nabilone 
(Fig. 8) [synthetic analogs of THC] have been the most 
widely investigated in clinical trials [156]. A randomized, 
double-blind, placebo-controlled study that investigated the 
effect of THC (1.5 mg administered three times daily for 
3 weeks) in 50 patients with dementia agitation or aggres-
sion found no significant differences between the treatment 
group and the placebo group (primary outcome measured 
using the NPI) [163]. Similarly, another trial showed no 
efficacy for THC in reducing agitation or aggression [164] 
(Table 3).
In contrast, a synthetic analog of THC, dronabinol, was 
found to be effective in reducing agitation in patients with 
dementia [156]. A retrospective study conducted on 40 
acutely hospitalized patients with severe dementia showed 
that dronabinol (7 mg/day for 2 weeks) significantly reduced 
motor agitation and aggressiveness (a significant decrease in 
all domains of the Pittsburgh Agitation Scale) [165]. How-
ever, some authors reported the occurrence of adverse effects 
associated with dronabinol use, with a particular emphasis 
on sedation [165, 166]. Other studies found that dronabi-
nol reduced night-time agitation [165, 167–169] in patients 
with dementia. An open-label pilot study of six patients with 
dementia with night-time agitation treated with dronabinol 
(2.5 mg/day for 2 weeks) reported a significant reduction in 
nocturnal motor activity [167] (assessed using the NPI scale) 
(Table 3). These encouraging results led to further interest 
in this class of compounds and the initiation of a clinical 
investigation of another synthetic cannabinoid, nabilone. 
First, the efficacy of nabilone has been only described in two 
case reports, which described the improvement of behavio-
ral disturbances (agitation and psychosis) in patients with 
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Fig. 8  Chemical structure and receptor affinity of dronabinol and 
nabilone [160, 161]. CB cannabinoid
257Dementia-Related Psychosis/Agitation/Aggression: A Review of Drug Candidates
randomized, double-blind, placebo-controlled cross-over trial 
(NCT02351882) [59] evaluated the safety and effectiveness 
of nabilone (1–2 mg) for 14 weeks (6-week treatment with a 
1-week washout between phases) in the management of agita-
tion in 39 patients with AD (primary outcome measured using 
CMAI) (Table 3). The authors reported a statistically signifi-
cant reduction in agitation within the nabilone group [60, 
61]. During the treatment, the patients treated with nabilone 
experienced sedation. The authors concluded that nabilone 
may constitute a promising treatment for agitation associated 
with AD; however, the obtained data should be confirmed in 
a longer and larger study and side effects such as sedation and 
possibly cognitive decline should be monitored [61]. Never-
theless, nabilone seems to have a greater effect in reducing 
agitation, compared with other cannabinoids such as THC 
and dronabinol [61] and offered the most favorable pharma-
cokinetic profile among all the studied cannabinoids [172]. 
Further clinical studies are warranted to confirm its efficacy.
4.7  Drugs Improving Sleep Quality Displaying 
Various Mechanisms of Action
4.7.1  Noradrenergic and Specific Serotonergic 
Antidepressant: Mirtazapine
Nocturnal sleep quality may contribute to the onset of 
behavioral problems in patients with dementia [173]. Clini-
cal observations suggested that agitative behavior in patients 
with dementia might be caused by sleep disturbances [174, 
175]. In this regard, it has been proposed that both condi-
tions could be effectively addressed by a drug that displays 
anxiolytic as well as sleep-promoting activity [176].
Mirtazapine is an antidepressant with sedative properties 
and an ability to promote sleep [177, 178]. It interacts with 
several types and subtypes of receptors including seroto-
nin 5-HT2AR and 5-HT3R, alpha-2 adrenoceptors, and  H1R 
(Fig. 9) [179]. The unique pattern of receptor modulation 
by mirtazapine not only ameliorates psychiatric symptoms 
but also helps to improve sleep quality [178]. The first pilot 
study evaluating the effect of mirtazapine (15–30 mg/day) on 
AD-related agitation was a 12-week open-label, prospective 
study that included 16 patients who had clinically significant 
agitation [176] (Table 3). The authors observed a significant 
reduction in agitation in the patients treated with mirtazap-
ine compared with pre-treatment with mirtazapine (changes 
in behavior were assessed using CMAI-Short Form) [176]. 
These encouraging data prompted the initiation of a larger 
phase III, pragmatic, multi-center, double-blind, placebo-
controlled, randomized study (NCT03031184), which is 
currently recruiting 222 patients to evaluate the safety and 
effectiveness of mirtazapine (15–30 mg/day for 12 weeks) in 
reducing AD-related agitation (primary outcome measure: 
CMAI score at 12 weeks) [75].
4.8  α2δ Subunit‑Containing Voltage‑Dependent 
Calcium Channel Blocker: Gabapentin
In a large percentage of patients with dementia, agitation 
and wandering manifest during the night-time [173]. The 
nocturnal episodes of behavioral disturbances have a nega-
tive influence on daily functioning and additionally induce 
aggression during the day [173]. This vicious circle might 
be broken by treatment with a sedative agent that can help 
to decrease agitation and improve sleep quality during the 
night.
In 2011, a case report described the effectiveness of 
gabapentin in reducing the dementia-associated noctur-
nal agitation [181]. Gabapentin is an FDA-approved drug 
for the treatment of epilepsy [182]. Gabapentin blocks 
the α2δ subunit-containing voltage-dependent calcium 
channels (Fig. 10), which are associated with the release 
of neurotransmitters [183, 184]. Gabapentin displays a 
versatile pharmacological profile, including anticonvul-
sant, sedating, and anxiolytic activities [185]. In addition, 
the positive effects of gabapentin on the sleep quality and 
architecture have been well documented [186]. A series of 
case reports have described the treatment of patients with 
dementia with agitation using gabapentin and showed that 
the patients responded to the treatment favorably [187, 188]. 
Currently, gabapentin is being investigated in a phase IV 
study (NCT03082755) to test its effect (300–600 mg/day) on 
night-time agitation (primary outcome measure: night-time 
agitation measured using CMAI) [119]. During the 8-week 
treatment, this double-blind, placebo-controlled, randomized 
clinical trial will enroll 136 participants [76]. The remain-
ing options available for the treatment of sleep disturbances 
and nocturnal agitation such as benzodiazepines are not rec-
ommended in vulnerable elderly individuals because these 
agents are well documented to cause harmful effects such 
as cognitive worsening and increase the risk of fall-related 
injuries [189].
Fig. 9  Chemical structure and 
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5  Compounds in the Early Stage 
of Development (Discovery or Preclinical 
Phase)
We additionally searched for literature data associated with 
the identified compounds in the early stage of development 
(discovery or preclinical phase), published from 2014 to the 
present day to obtain the most recent overview covering the 
last 5 years, using the compounds’ name and other keywords 
such as “Alzheimer’s disease” and “dementia” or “aggres-
sion” or “psychosis.” We used PubMed, ScienceDirect, 
GlobalData, and Google Scholar databases for our search 
(papers written in English). If data regarding the identified 
compounds were not published, we searched the websites of 
pharmaceutical and biotech companies responsible for the 
compounds’ development. Several molecules that matched 
the selection criteria were identified, which are described 
in detail below.
5.1  Multi‑Target‑Directed Ligand Concept
It has been suggested that parallel modulation of several 
molecular targets may result in a balanced, and thus supe-
rior, pharmacological action, compared to a selectively 
acting drug. Considering this, a novel approach in drug 
discovery involves designing a single chemical entity that 
can simultaneously modulate the activity of several biologi-
cal targets. Such compounds are described in the literature 
as “multi-target-directed ligands” [197]. The multi-target-
directed ligand concept intended to design “clean” ligands 
that bind to selected molecular targets while sparing off 
targets, and thus reduce the risk of side effects [198]. The 
multi-target-directed ligand concept is relatively new; how-
ever, it has recently been widely explored in the literature 
and several experimental compounds have emerged from 
this strategy.
5.1.1  Ligands Targeting Several Monoaminergic Receptors
A combination of chemical scaffolds responsible for inter-
action with 5-HT6R/5-HT7R and 5-HT2AR/D2R yielded a 
hybrid molecule 1, which elicited favorable psychotropic 
effects (Fig. 11). In pharmacological studies, the selected 
multi-modal ligand 1 showed antidepressant and antipsy-
chotic activity and did not affect cognition, in contrast to the 
eight antipsychotic drugs tested in the same experimental 
setting [199].
Similarly, a series of multi-modal ligands exhibiting high 
affinity to SERT,  D2R, 5-HT1AR, 5-HT6R, and 5-HT7R have 
been identified (Fig. 11). It has been shown that tetrahy-
dropyridin-4-yl‐1H‐indole is a privileged scaffold, which 
accounts for an interaction with SERT,  D2R and 5-HT1AR, 
and its combination with the aryl sulfonamide moiety pro-
vides additional interaction with 5-HT6R and 5-HT7R. The 
selected compound 2 was tested in vivo and found to exhibit 
antipsychotic and antidepressant activity, as well as exert 
memory-enhancing effects [200].
Another notable approach of identifying novel MTLDs 
relies on combining  D2R partial agonism with 5-HT6R 
antagonism. The partial  D2 agonism concept is based on 
the modulation of dopaminergic neurotransmission at a low 
sufficient level that simultaneously prevents the occurrence 
of extrapyramidal side effects by preventing excessive  D2R 
blockade in the striatum [201]. This strategy resulted in the 
development of a series of hybrid molecules, combining 
the 5-HT6 and  D2 pharmacophores (Fig. 11). The selected 
molecule 3 displayed antidepressant and anxiolytic activity 
in aged animals, as well as promising procognitive effects 
[201]. The abovementioned compounds (2 and 3) are cur-
rently at an early stage of development by Adamed Pharma 
[202, 203].
5.1.2  Molecules Targeting Muscarinic  M1 and  M4 Receptors
Modulation of muscarinic receptors activity may improve 
both cognitive and psychosis-related symptoms. Targeting 
the centrally located  M1R and  M4R proved to enhance the 
memory function and reduce psychosis both in animal mod-
els and in clinics [204, 205]. Additionally, stimulation of 
muscarinic receptors controls the increase of amyloid-β lev-
els and prevents memory impairments [206]. This evidence 
encouraged the development of dual ligands acting on  M1R/
M4R. Sosei Heptares, jointly with Allergan, is developing a 
series of dual  M1/M4 agonists for the treatment of memory 
deficits and comorbid psychosis in patients with AD. The 
joint project has progressed to an advanced preclinical devel-
opment stage [207]. Further data have not been revealed.
5.1.3  Cholinesterase and Monoamine Oxidase Inhibitor: 
Ladostigil
Degeneration of cholinergic cortical neurons is considered 
as a key pathology that accounts for the cognitive deficit in 
patients with AD. Drugs that act by inhibiting cholinester-
ase, and as a result, increasing cholinergic transmission in 
the affected cortical areas are expected to improve memory 
function. Interestingly, a cholinesterase inhibitor rasagiline 
reduced aggression and delusions in patients with AD [208]. 
Fig. 10  Chemical structure and 
binding profile of gabapentin 
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In a dual-acting drug, ladostigil, the carbamate fragment of 
rivastigmine, which accounts for the inhibition of cholinest-
erases, was merged with the N-(prop-2-yn-1-yl)-2,3-dihy-
dro-1H-inden-1-amine fragment of rasagiline, which blocks 
the activity of monoamine oxidases A and B (Fig. 12) [209]. 
Ladostigil is a multi-modal agent developed by Avraham 
Pharmaceuticals to treat patients with mild cognitive impair-
ment with concomitant behavioral symptoms. Preclinical 
studies showed that ladostigil improves memory deficits and 
exerts anxiolytic and antidepressant-like activity [210, 211]. 
Therefore, ladostigil has been suggested for use in patients 
with dementia with comorbid depression; however, no clini-
cal data are available so far [210].
5.1.4  Ligands Targeting Serotonin 5‑HT6 and 5‑HT2A 
Receptors
Serotonin 5-HT6 receptors are localized in the cortical 
and limbic areas, and ligands modulating the activity of 
5-HT6 receptors exert memory-enhancing, anxiolytic, and 
antidepressant effects [47, 48]. Importantly, several selec-
tive 5-HT6 antagonists entered clinical trials and have been 
regarded as potential drug candidates for the treatment of 
cognitive impairment associated with AD [48, 212].
Similarly, serotonin 5-HT2A receptor has emerged as a 
promising target for the treatment of AD, owing to its strong 
relationship with the pathology of dementia-related psycho-
sis (see Sect. 2). Therefore, merging 5-HT2AR and 5-HT6R 
into a single chemical entity, having the pharmacological 
activities of both the receptors, may be beneficial in the 
treatment of dementia-related psychosis. Small molecules 
targeting 5-HT6R and 5-HT2AR are currently under devel-
opment (discovery phase/advanced preclinical development 
stage) for the treatment of dementia-related psychosis by 
Adamed Pharma [213]. The chemical structure and preclini-
cal data have not been disclosed.




Previous studies indicated that patients with dementia were 
found to be particularly sensitive to side effects induced by 
atypical antipsychotics [214]. Patients with dementia seem 
to be at a greater risk of developing antipsychotic-associated 
stroke events [215]. It should be emphasized that atypical 
antipsychotics used so far in clinical settings (risperidone, 
olanzapine, quetiapine, and aripiprazole) interact with mul-
tiple receptors, including “off targets,” which induce seri-
ous side effects (Table 4). For instance, similar to the first 
Fig. 11  Examples of multi-target-directed ligands obtained by combining the scaffolds responsible for interactions with 5-HT6R, 5-HT7R, 
5-HT2AR, and  D2R (discovery stage). SERT serotonin transporter
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generation of antihistamines, antipsychotic agents tend to 
induce excessive daytime sleepiness owing to their high 
affinity to  H1R present in the brain [216]. Interaction with 
alpha-adrenoceptors (risperidone and quetiapine) causes 
orthostatic hypotension, and as a result, may increase the 
risk of falls and hip fractures [217]. Moreover, a large clini-
cal study found a correlation between the increased risk of 
stroke and treatment with antipsychotics that exhibit high 
binding affinity to alpha-2 adrenoceptor and  M1R. A pos-
sible mechanism underlying this relationship is that block-
ade of alpha-2 adrenoceptor and  M1 may induce orthos-
tatic hypotension and tachycardia, which prompts unstable 
hemodynamic conditions and increases the risk of stroke 
[214, 215]. In addition, blockade of the muscarinic recep-
tors intensifies the cholinergic deficit and worsens cogni-
tive functioning in patients with dementia, who already 
have memory impairment. Blockade of  M1R may induce 
additional uncomfortable symptoms, such as severe con-
stipation and urine retention [218]. Furthermore, previous 
studies showed that inhibition of hERG (human ether-a-
go–go-related gene) potassium channel has been considered 
as the most common mechanism of drug-induced cardiotox-
icity (prolongation of QT interval). Therefore, evaluation of 
the potential inhibitory effects on the hERG channel should 
become an obligatory safety practice in the early stages of 
drug discovery for dementia-related psychosis and agitation/
aggression [219, 220].
Considering the safety issues regarding elderly patients 
and their particular sensitiveness to adverse reactions, future 
therapeutic agents designed for dementia-related psychosis 
and agitation/aggression should not antagonize the mus-
carinic, adrenergic, and histaminergic receptors or the hERG 
channel [112].
7  Conclusions and Future Perspectives
Treatments currently used for dementia-related psychosis 
and agitation/aggression pose a great challenge to clinicians, 
and specifically targeted pharmacotherapies are lacking. 
Despite known harms and modest clinical efficacy, antipsy-
chotics still are often administered off-label to control some 
symptoms [221]. Several clinical experts have agreed that to 
optimize the clinical response, patients with dementia should 
be treated with specifically developed medications that inter-
act with pharmacologically relevant targets [16, 222, 223]. 
Within this context, preclinical and clinical studies have 
pointed out various biological targets that might constitute 
potential therapeutics for dementia-related psychosis and 
agitation/aggression.
Considering that the polymorphism of serotonin 5-HT2AR 
and its disrupted functioning has been associated with the 
onset of psychosis and aggression in AD, it seems justifi-
able that the ligands modulating the activity of 5-HT2AR 
could be attractive therapeutic agents for dementia-related 
psychosis and aggression [26, 27, 82]. A selective inverse 
agonist of 5-HT2AR (pimavanserin) and novel atypical antip-
sychotics acting as 5-HT2A antagonists (lumateperone, brex-
piprazole) have advanced to phase III clinical trials after 
Fig. 12  Chemical structure 
of ladostigil. Ladostigil is 
composed of two fragments: the 
carbamate moiety of rivastig-
mine, which accounts for the 
inhibition of cholinesterases, 
merged with the N-(prop-2-yn-
1-yl)-2,3-dihydro-1H-inden-1-
amine fragment of rasagiline, 
which blocks the monoamine 
oxidases (MAO) A and B [209]
Table 4  Simplified representation of an off-target receptor profile





 H1 Excessive sedation, weight gain
 M1 Memory deficits, anticholinergic side 
effect
 hERG channel QT prolongation, arrhythmia
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showing promising efficacy in phase II studies in the man-
agement of dementia-related psychosis and agitation [58, 
73, 114]. A phase III study has reported promising results 
for brexpiprazole, which significantly reduced agitation in 
patients with dementia, and its long-term efficacy will be 
further evaluated in a treatment-extension study [114]. In 
contrast, a phase III clinical trial that investigated the effi-
cacy of lumateperone in reducing dementia-related agita-
tion has been terminated because of a lack of efficacy [119]. 
Moreover, several compounds targeting 5-HT2AR are in the 
early stage of the drug discovery process [199, 213]. In addi-
tion, the role of 5-HT1AR is well elucidated in the onset 
of neuropsychiatric symptoms [34]. A 5-HT1AR/5-HT1BR 
agonist eltoprazine has also completed phase II clinical 
trials, showing positive results in suppressing AD-related 
aggression. Similarly, pathological changes in the function 
of alpha-1 adrenoceptor have been linked with the onset of 
aggressive behavior in patients with AD [148]. A centrally 
acting alpha-1 adrenergic antagonist prazosin is currently 
being investigated in a phase II study in the treatment of 
dementia-related aggression.
Several groups of patients with dementia with comorbid 
conditions may require specific adjusted pharmacological 
treatment. The episodes of nocturnal agitation in patients 
with dementia seem to require an agent displaying sedative 
properties and adjunctive sleep-promoting activity [174]. 
Within this context, two generic drugs, mirtazapine and 
gabapentin, are currently being investigated in phase III and 
phase IV trials, respectively. Both agents exhibit sedative 
properties and the ability to improve sleep quality, which 
may be suitable for this subgroup of patients.
Molecules acting via the inhibition of SERT appear to 
constitute another class of promising therapeutics [32, 33]. 
Polymorphism of the SERT has been associated with AD-
related aggression. Significant clinical efficacy of a selec-
tive SERT inhibitor, citalopram, has been observed in a 
phase III clinical trial. However, citalopram induced cardiac 
side effects, and therefore, its long-term clinical applica-
tion remains dubious. Currently, a phase III clinical trial is 
recruiting patients to evaluate the safety and efficacy of the 
S-enantiomer of citalopram, escitalopram, in reducing AD-
related aggression. Escitalopram seems to be a safer alter-
native and does not tend to induce risky cardiac reactions 
[106]. It is worth nothing that dextromethorphan displays 
high affinity to SERT, which further supports the evalua-
tion of its combined formulations (AVP-786 and AXS-05) in 
clinical trials. Both formulations are currently being inves-
tigated in ongoing phase III studies. The interim analysis 
of the study with AXS-05 showed promising outcomes and 
reported no safety issues [63].
Although certain drug candidates presented here act on 
the molecular targets that do not meticulously match the 
pathology of dementia-related psychosis and agitation/
aggression, their promising pharmacological profile suggests 
their potential therapeutic utility. Favorable pharmacological 
properties have been reported for mGluR2,  CB1, NMDA, 
 M4, and  M1/M4 agonists. A  CB1R agonist, nabilone, showed 
efficacy in reducing aggression in patients with dementia in 
a recently completed phase II/III clinical trial. An mGluR2 
agonist, LY2979165, has advanced to phase II clinical trials 
that will investigate its safety and efficacy in the treatment 
of dementia-related psychosis and agitation/aggression. 
Similarly, an indirect NMDA agonist compound SND-51 
has advanced to phase II clinical trials that will evaluate 
its efficacy in the treatment of dementia and psychosis. A 
selective  M4 receptor agonist, HTL0016878, has progressed 
to phase I clinical trials. In addition, various compounds 
acting on the pharmacologically relevant targets (5-HT6R 
and  M1R/M4R) have progressed to an advanced preclini-
cal development stage. To sum up, future drugs targeting 
mGluR, NMDA receptors,  CB1R,  M1/M4R, and 5-HT6R also 
offer the possibility to tackle dementia-related psychosis and 
agitation/aggression.
Additionally, the key success of a clinically effective 
agent will likely depend on its safety and lack of harmful 
side effects [8, 9, 11]. Considering that previous clinical 
observations have shown that patients with dementia are 
at a higher risk of stroke [112], future drug candidates for 
patients with dementia should consistently avoid interactions 
and further blockade of alpha-2 adrenoceptors,  M1R,  H1R, 
and the hERG channel to avoid cardiotoxicity, stroke, exces-
sive sedation, and memory impairments.
Nevertheless, the future pharmacotherapy of dementia-
related psychosis, agitation/aggression will likely depend on 
the successful compilation of phase III clinical trials and fur-
ther approvals. So far, the most promising results have been 
observed for compounds modulating serotoninergic signal-
ing. Another set of molecules displaying favorable pharma-
cological activity are at an early stage of development.
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